Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy
暂无分享,去创建一个
J. Hugosson | J. Damber | Jonas Hugosson | A. Khatami | Jan-Erik Damber | Ali Khatami | Wanzhong Wang | Wanzhong Wang
[1] Lennart Franzén,et al. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. , 2006, The Journal of urology.
[2] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[3] B. Trock,et al. Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.
[4] C. Abbou,et al. EAU guidelines on prostate cancer. , 2009, European urology.
[5] K. Ali,et al. PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section , 2006 .
[6] S. Nordling,et al. Ki-67, p53, ER Receptors, Ploidy and S Phase as Long-Term Prognostic Factors in T1 Node-Negative Breast Cancer , 2006, Tumor Biology.
[7] C. Bangma,et al. Overdiagnosis and overtreatment of early detected prostate cancer , 2007, World Journal of Urology.
[8] D. Neal,et al. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. , 1992, British journal of urology.
[9] M. Roobol,et al. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 1997, The Prostate.
[10] J W Moul,et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. , 1996, The Journal of urology.
[11] Hans Garmo,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.
[12] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[13] P. Lipponen,et al. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. , 1997, European urology.
[14] V. Khoo,et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] T. Stamey,et al. Clinical observations on the doubling time of prostate cancer. , 1993, European urology.
[16] L. Klotz,et al. Active surveillance versus radical treatment for favorable-risk localized prostate cancer , 2006, Current treatment options in oncology.
[17] A. Llombart‐Bosch,et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. , 2005, European urology.
[18] A. Bergh,et al. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. , 1997, The Journal of urology.
[19] L. Denis,et al. The European randomized study of screening for prostate cancer , 1997, Cancer.
[20] E. Bergstralh,et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. , 2001, Mayo Clinic proceedings.
[21] M. Roobol,et al. The story of the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.
[22] Hans Lilja,et al. Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma , 2004, Cancer.
[23] M. Hammond,et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.